Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Shire's bid to block Lialda copies hits another snag

Shire shares slumped Thursday after a U.S. Appeals Court denied its latest attempt to fend off generic versions of its ulcerative colitis treatment Lialda. The drug is one of Shire's top sellers--and the case is one of the first reviewed under a U.S. Supreme Court patent-law ruling.

Merck's 'landmark' Zetia data hits NEJM, giving a boost to all LDL-fighting meds

The nitty-gritty on Merck & Co.'s Zetia outcomes trial is now revealed--and it's not just good news for the cholesterol-fighting drug and its combo-pill sister Vytorin. It's good for all high-powered cholesterol meds.

Jury sides with Merck and its execs in gender-bias case

Merck & Co. won the day in a gender discrimination suit on Tuesday, as a federal jury found that former employee Kerri Colicchio failed to prove she was discriminated against because of her pregnancy.

Roche unchallenged at top of cancer sellers, but Celgene could fight Novartis for No. 2

Roche has been at the top of the heap in oncology sales for years--and it's no wonder, what with its top-selling triumvirate, Herceptin, Rituxan and Avastin. The Swiss drugmaker racked up more than $25 billion in cancer last year, and its closest challenger, Novartis, managed less than half of that.

Is Pozen prepping to sell out? Sudden CEO exit, new Irish subsidiary hint yes

Pozen has had its share of woes in recent months: Manufacturing problems at its contract supplier tanked new drug applications twice in a row, and Big Pharma partner Sanofi bailed on their development deal for the new-and-improved aspirins.

Hep C drug tourism has begun as patients seek Harvoni, Sovaldi overseas

Everyone from individual patients on up to pharmacy benefits managers has been scheming about how to get Gilead's Harvoni and Sovaldi at the lower prices available in other countries--as low as 1% of the U.S. sticker price, Bloomberg notes.

Top oncologist joins chorus of pricing critics in high-profile ASCO speech

Pharma types are getting a wee bit defensive about critics' attacks on cancer drug prices, if response to FiercePharma's recent coverage is any indication. But the criticism just keeps on coming, even as drugmakers work with payers behind the scenes on mutually acceptable pricing deals.

Betting on Pfizer merger--or CEO goodbye--traders go bullish on Glaxo

Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.

How well paid are pharma execs? Best in healthcare, survey shows

How does pharma executive pay compare with the rest of healthcare? Forbes columnist Dan Munro decided to find out--and the answer is that drugmakers pay their top managers more than in any other slice of the healthcare industry.

FTC scores hefty $1.2B settlement in Teva pay-for-delay case

After pursuing a pay-for-delay case against Teva's Cephalon unit for years, the Federal Trade Commission has forced the drugmaker to hand over $1.2 billion in past profits.